Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
111.31
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 7, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
111.31
Bid (Size)
107.16 (1)
Ask (Size)
113.24 (1)
Prev. Close
111.31
Today's Range
111.31 - 111.31
52wk Range
70.73 - 117.77
Shares Outstanding
183,352,255
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
February 03, 2023
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...
Via
Benzinga
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
January 30, 2023
Via
Benzinga
Performance
YTD
+10.64%
+10.64%
1 Month
+3.93%
+3.93%
3 Month
+37.00%
+37.00%
6 Month
+16.31%
+16.31%
1 Year
+24.55%
+24.55%
More News
Read More
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
Via
Benzinga
What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical
January 30, 2023
Via
Benzinga
6 Analysts Have This to Say About Biomarin Pharmaceutical
January 11, 2023
Via
Benzinga
2 Top Biotech Stocks Defying the Bear Market
January 10, 2023
Via
The Motley Fool
3 Drug Stocks With Promising Pipelines for 2023
January 23, 2023
Via
InvestorPlace
Cramer Is Holding This Biotech Stock
January 12, 2023
Via
Benzinga
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
January 11, 2023
Via
Investor's Business Daily
BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target
January 11, 2023
Via
Benzinga
Top Picks For 2023: Catalyst Pharmaceuticals
January 02, 2023
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 01, 2022
Via
Benzinga
Expert Ratings for Biomarin Pharmaceutical
November 29, 2022
Via
Benzinga
Expert Ratings for Biomarin Pharmaceutical
October 31, 2022
Via
Benzinga
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
October 27, 2022
Via
The Motley Fool
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
December 01, 2022
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
November 29, 2022
Via
Benzinga
Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate
November 23, 2022
Via
Benzinga
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
November 23, 2022
Via
Investor's Business Daily
Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today
November 23, 2022
Via
Benzinga
$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying
November 03, 2022
Via
Benzinga
10 Analysts Have This to Say About Biomarin Pharmaceutical
October 31, 2022
Via
Benzinga
Mastercard To $428? Plus This Analyst Slashes PT On Intel
October 31, 2022
Via
Benzinga
Biomarin Pharmaceutical: Q3 Earnings Insights
October 26, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
October 31, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.